Literature DB >> 19888977

Novel in vitro model for studying ureteric stent-induced cell injury.

Chelsea N Elwood1, Dirk Lange, Richard Nadeau, Shannon Seney, Kelly Summers, Ben H Chew, John D Denstedt, Peter A Cadieux.   

Abstract

OBJECTIVE: To develop a novel in vitro model for the study of bladder and kidney epithelial cell injury akin to stent movement, as ureteric stents are associated with urinary tract complications that can significantly add to patient morbidity. These sequelae may be linked to inflammation triggered by stent-mediated mechanical injury to the urinary tract.
MATERIALS AND METHODS: T24 bladder and A498 kidney cell line monolayers were damaged mechanically by segments of either Percuflex Plus (PP) or Triumph (triclosan-eluting) stents (both from Boston Scientific Corporation Inc. Natick, MA, USA) and the resulting expression profiles of several pro-inflammatory cytokines and growth factors were analysed.
RESULTS: After control injury using the PP stent, supernatants of both cell lines had significantly increased levels of interleukin (IL)-6, IL-8, basic fibroblast growth factor and platelet-derived growth factor BB, and A498 cells also had increased tumour necrosis factor alpha. In almost all cases, the presence of triclosan within the media abrogated the pro-inflammatory cytokine increases, while its effects on growth factors varied.
CONCLUSION: This study suggests that stent-related symptoms in the bladder and kidney may be partially due to a local inflammatory response to epithelial damage caused by the presence and movement of the stent. Future stent design should take these inflammatory responses, with respect to physical injury, into consideration, using either more biocompatible materials or anti-inflammatory compounds such as triclosan.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19888977     DOI: 10.1111/j.1464-410X.2009.09001.x

Source DB:  PubMed          Journal:  BJU Int        ISSN: 1464-4096            Impact factor:   5.588


  7 in total

1.  Update on ureteral stent technology.

Authors:  Dirk Lange; Ben H Chew
Journal:  Ther Adv Urol       Date:  2009-08

2.  Cell-penetrating peptide CGKRK mediates efficient and widespread targeting of bladder mucosa following focal injury.

Authors:  James I Griffin; Siu Kit Kevin Cheng; Tomoko Hayashi; Dennis Carson; Manju Saraswathy; Devatha P Nair; Dmitri Simberg
Journal:  Nanomedicine       Date:  2017-04-17       Impact factor: 5.307

3.  In vivo assessment of a novel biodegradable ureteral stent.

Authors:  Alexandre A Barros; Carlos Oliveira; Ana J Ribeiro; Riccardo Autorino; Rui L Reis; Ana Rita C Duarte; Estevão Lima
Journal:  World J Urol       Date:  2017-11-11       Impact factor: 4.226

Review 4.  Ureteral stent technology: Drug-eluting stents and stent coatings.

Authors:  Luo Yang; Samantha Whiteside; Peter A Cadieux; John D Denstedt
Journal:  Asian J Urol       Date:  2015-09-21

5.  East Indian Sandalwood Oil Is a Phosphodiesterase Inhibitor: A New Therapeutic Option in the Treatment of Inflammatory Skin Disease.

Authors:  Manju Sharma; Corey Levenson; John C Browning; Emily M Becker; Ian Clements; Paul Castella; Michael E Cox
Journal:  Front Pharmacol       Date:  2018-03-09       Impact factor: 5.810

6.  Encrustations on ureteral stents from patients without urinary tract infection reveal distinct urotypes and a low bacterial load.

Authors:  Matthias T Buhmann; Dominik Abt; Oliver Nolte; Thomas R Neu; Sebastian Strempel; Werner C Albrich; Patrick Betschart; Valentin Zumstein; Antonia Neels; Katharina Maniura-Weber; Qun Ren
Journal:  Microbiome       Date:  2019-04-13       Impact factor: 14.650

Review 7.  Advances in ureteral stents.

Authors:  Hilary Brotherhood; Dirk Lange; Ben H Chew
Journal:  Transl Androl Urol       Date:  2014-09
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.